MAPT and psychotic disorder: We raise this issue as in patients receiving an investigational treatment in conjunction with an amyloid-beta monoclonal antibody treatment–and potentially anti-tau therapies in the future–there is the potential for these novel antibody treatments to alter the symptoms of psychosis either favorably, unfavorably, or both, which could confound the interpretation of the investigational product’s efficacy (50).